Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance

Published:2024-10 Issue: Volume:55 Page:101482
ISSN:2352-5789
Container-title:Gynecologic Oncology Reports
language:en
Short-container-title:Gynecologic Oncology Reports

Author:

Nakao Takehiro^ORCID,Harano Kenichi^ORCID,Wakabayashi Masashi^ORCID,Naito Yoichi^ORCID,Tanabe Hiroshi^ORCID,Mukohara Toru^ORCID

Publisher

Elsevier BV

Reference18 articles.

1. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011

2. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer;Coleman;N. Engl. J. Med.,2019

3. Platinum resistance in ovarian cancer: role of DNA repair;Damia;Cancers (basel),2019

4. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 Trial;DiSilvestro;J. Clin. Oncol.,2023

5. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial;Frenel;Ann. Oncol.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP